IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v28y2010i1p47-60.html
   My bibliography  Save this article

Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US

Author

Listed:
  • Virginia Rosen
  • Douglas Taylor
  • Hemangi Parekh
  • Ankur Pandya
  • David Thompson
  • Andreas Kuznik
  • David Waters
  • Michael Drummond
  • Milton Weinstein

Abstract

Background: A recent study found fewer hospitalizations for congestive heart failure (CHF) patients receiving high-dose versus low-dose statin therapy. Objective: To examine the cost effectiveness of high-dose versus low-dose statin therapy in CHF patients. Methods: Two scenarios (literature-based [base-case scenario] vs trial-based post-event mortality [alternative scenario]) assessed the cost effectiveness of atorvastatin 80mg/day (A80) versus atorvastatin 10 mg/day (A10) in patients with both CHF and coronary heart disease (CHD) [CHF/CHD], using a lifetime Markov model. The model predicts treatment-specific probabilities of major and minor cardiovascular events and death, based on clinical trial data. The quality of life and costs were literature based. Measures included costs per life-year saved (LYS) and QALY gained. Health consequences and costs were discounted at 3.0% annually. Analyses were conducted from the payer perspective and valued in $US, year 2006–7 values. Results: Literature-based mortality estimates (base case) increased life-years and QALYs for A80 compared with A10 (incremental cost-effectiveness ratios [ICERs]: $US9600 per LYS; $US13 600 per QALY). At a willingness to pay of $US100 000 per QALY, A80 was cost effective in 80% of simulations. A10 dominated A80 when using trial-based mortality estimates (alternative scenario). At a willingness to pay of $US100 000 per QALY, A80 was cost effective in 48% of simulations. Conclusions: Intensive A80 treatment may be cost effective versus A10 in cardiovascular prevention in CHF/CHD patients in the US, due to projected gains in life expectancy and health-related quality of life. However, the results are highly sensitive to assumptions about the mortality rate in the model. When using the mortality rate observed in the trial, A10 dominates A80. Copyright Adis Data Information BV 2010

Suggested Citation

  • Virginia Rosen & Douglas Taylor & Hemangi Parekh & Ankur Pandya & David Thompson & Andreas Kuznik & David Waters & Michael Drummond & Milton Weinstein, 2010. "Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US," PharmacoEconomics, Springer, vol. 28(1), pages 47-60, January.
    • Handle: RePEc:spr:pharme:v:28:y:2010:i:1:p:47-60
    DOI: 10.2165/11531440-000000000-00000
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/11531440-000000000-00000
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/11531440-000000000-00000?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Douglas Taylor & Ankur Pandya & David Thompson & Paula Chu & Jennifer Graff & James Shepherd & Nanette Wenger & Heiner Greten & Rafael Carmena & Michael Drummond & Milton Weinstein, 2009. "Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(3), pages 255-265, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Lisa G Suter & A David Paltiel & Benjamin N Rome & Daniel H Solomon & Thomas S Thornhill & Stanley K Abrams & Jeffrey N Katz & Elena Losina, 2013. "Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty," PLOS ONE, Public Library of Science, vol. 8(5), pages 1-10, May.
    2. Paddy Gillespie & Eamon O’Shea & Andrew Murphy & Susan Smith & Mary Byrne & Molly Byrne & Margaret Cupples, 2012. "Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 429-443, August.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:28:y:2010:i:1:p:47-60. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.